| DC Field | Value | Language |
|---|
| dc.contributor.author | Denisyuk, T. A. | - |
| dc.contributor.author | Lazareva, G. A. | - |
| dc.contributor.author | Provotorov, V. Y. | - |
| dc.contributor.author | Shaposhnikov, A. A. | - |
| dc.date.accessioned | 2022-04-26T09:47:18Z | - |
| dc.date.available | 2022-04-26T09:47:18Z | - |
| dc.date.issued | 2016 | - |
| dc.identifier.citation | Endothelium and cardioprotective effects of hmg-co-a-reductase in combination with l-arginine In endothelial dysfunction modeling / T.A. Denisyuk [et al.] // Research Result: Pharmacology and Clinical Pharmacology. - 2016. - Vol. 2, № 1(2).- P. 4-8. - Doi: 10.18413/2313-8971-2016-2-1-4-8. - Refer.: p. 7-8. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46368 | - |
| dc.description.abstract | Using the combined application of L-arginine with HMG-Co-A reductase inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the background of modeling of sepsis-induced disease through the introduction of strain 603 Staphylococcus aureus shows endotelio- and cardioprotective effects | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | endothelial dysfunction | ru |
| dc.subject | HMG-Co-A reductase inhibitor simvastatin | ru |
| dc.subject | atorvastatin | ru |
| dc.subject | rosuvastatin | ru |
| dc.subject | endotoxin | ru |
| dc.title | Endothelium and cardioprotective effects of hmg-co-a-reductase in combination with l-arginine In endothelial dysfunction modeling | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 2, № 1
|
